

1
2
3
4
5
6
7
8
9
10
11
12

**UNITED STATES DISTRICT COURT
FOR THE CENTRAL DISTRICT OF ILLINOIS**

LINDA SCHWESKA, and DANIEL P.
SCHWESKA, her husband,

Plaintiffs,

vs.

C.R. BARD, INC., a foreign corporation,
BARD PERIPHERAL VASCULAR, INC.,
an Arizona corporation, and DOES 1 through
100 inclusive,

Defendants.

Docket No. _____

COMPLAINT FOR DAMAGES

- 1. NEGLIGENCE**
- 2. FAILURE TO WARN**
- 3. DESIGN DEFECT**
- 4. MANUFACTURING DEFECT**
- 5. BREACH OF IMPLIED WARRANTY**
- 6. NEGLIGENT MISREPRESENTATION**
- 7. LOSS OF CONSORTIUM**

DEMAND FOR A JURY TRIAL

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Plaintiffs, LINDA SCHWESKA and DANIEL P. SCHWESKA, Individually and as husband and wife, by and through their undersigned attorneys, hereby sue defendants C.R. BARD, INC.; BARD PERIPHERAL VASCULAR, INC.; and DOES 1 through 100 (collectively, the "Defendants") and allege as follows:

PARTIES

Plaintiffs

1. Plaintiffs, Linda Schweska and Daniel P. Schweska at all times relevant to this action resided in and continues to reside in Springfield, Illinois. On or about November 10, 2006, Linda Schweska underwent placement of a G2® filter or G2 Filter System® (hereafter G2®, G2 Filter® or G2 Filter System®). There were three failed explant attempts to remove the G2® filter. The first and second failed attempt to remove the G2® filter on January 2, 2007. The third failed attempt to remove the G2® filter occurred on March 7, 2007. The G2 Filter System® subsequently failed and a fourth attempt to remove the filter became necessary through open procedure. Specifically, the inferior vena cava filter had migrated and the tip of the filter was so embedded that retrieval was very difficult for the Plaintiff's physicians. Plaintiffs have incurred significant medical expenses and have endured extreme pain and suffering, loss of enjoyment of life, disability, and other losses.

Defendants

2. Defendant C.R. Bard, Inc. (“Bard”) is a corporation duly organized and existing under the laws of the state of Delaware and has its principal place in New Jersey. Bard at all times relevant to this action, designed, set specifications, manufactured, prepared, compounded, assembled, processed, marketed, distributed, and sold the Recovery® Filter System and G2® Filter System to be implanted in patients throughout the United States, including Illinois.

3. Defendant Bard Peripheral Vascular, Inc. (“BPV”) is a wholly owned subsidiary corporation of defendant Bard, with its principal place of business at 1625 West 3rd Street, Tempe, Arizona. BPV at all times relevant to this action, designed, set specifications, manufactured, prepared, compounded, assembled, processed, marketed, distributed, and sold the Recovery® Filter System and the G2® Filter System to be implanted in patients throughout the United States, including Illinois.

4. All references to “Defendants” hereafter shall refer to defendants Bard, BPV, and DOES 1 through 100.

5. The true names, identities, or capacities, whether individual, associate, corporate or otherwise of defendants, DOES 1 through 100, inclusive, are unknown to plaintiffs who, therefore, sues said defendants by such fictitious names. When the true names, identities or capacities of said fictitiously designated defendants are ascertained, plaintiffs will seek leave of Court to amend this complaint to insert the true names, identities, and/or capacities of DOE Defendants, together with the proper charging allegations against said DOE Defendants.

6. Plaintiffs are informed and believe, and thereon allege that each of the defendants sued herein as a DOE defendant is responsible in some manner for the acts, omissions, and conduct, which proximately resulted in and/or was a substantial contributing factor in Plaintiffs’ injuries.

JURISDICTION AND VENUE

7. Plaintiffs have suffered damages in an amount that exceeds the jurisdictional minimum of this Court.

8. This Court has jurisdiction over this action pursuant to 28 U.S.C. § 1332 because there is complete diversity of citizenship between the parties and the amount in controversy exceeds \$75,000.00

1 exclusive of costs and interests.

2 9. Venue in this district is appropriate under 28 U.S.C. § 1391 because a substantial part of
3 the events giving rise to this cause of action occurred in the District as defendants sold these products in
4 this District and have at all relevant times plaintiffs have resided in this District.
5

6 **GENERAL FACTUAL ALLEGATIONS**
7

8 10. Plaintiffs bring this case for serious personal injuries that Linda Schweska suffered as
9 result of a surgically implanted medical device, known as a G2 Filter System® (hereafter G2®, G2
10 Filter® or G2 Filter System®), migrating within her body and causing serious and ongoing physical,
11 emotional, and economic damages.

12 11. The G2® Filter was designed, manufactured, prepared, compounded, assembled,
13 processed, labeled, marketed, distributed, and sold by Defendants from approximately September 2005
14 to the present for the prevention of blood clots (thrombi) from travelling from the lower portions of the
15 body to the heart and lungs.

16 12. Prior to Plaintiff Linda Schweska being implanted with a G2® Filter on or about
17 November 10, 2006, Defendants knew and should have known that the device was defective and
18 unreasonably dangerous for, *inter alia*, the following reasons:

19 a. Defendants failed to conduct any clinical testing, such as animal studies, to determine
20 how the device would function once permanently implanted in the human body.

21 b. Defendants knew and/or should have known that the Recovery® Filter and G2 Filter
22 System had high rate fracture, migration, and excessive tilting and perforation the vena cava wall once
23 implanted in the human body. Defendants knew and/or should have known that such failures exposed
24 patients to serious injuries, including: death; hemorrhage; cardiac/pericardial tamponade; cardiac
25 arrhythmia and other symptoms similar to myocardial infarction; severe and persistent pain;
26 perforations of tissue, vessels and organs; and inability to remove the device. Upon information and
27 belief, Defendants also knew or should have known that certain condition or post-implant procedures,
28 such as morbid obesity or open abdominal procedures, could affect the safety and integrity of the

1 device. Further, Defendants knew of should have known that these risks for Recovery® Filter and G2
2 Filter System were and are substantially higher than other similar devices.

3 c. Further, Defendants knew and/or should have known that the Recovery® Filter and
4 G2 Filter System contained conditions, which Defendants did not intend, which resulted in the device
5 not performing as safely and the ordinary consumer would expect.

6 d. Despite being aware of these risks, Defendants misrepresented, omitted, and/or failed to
7 provide adequate warnings of these risks or instructions for safe use.

8 e. Even when Defendants designed and began marketing what they alleged to be a device
9 that specifically reduced these risks, they still failed to issue a recall or notify consumers that a safer
10 device was available.

11 **A. INFERIOR VENA CAVA FILTERS GENERALLY**

12 13. Inferior vena cava (“IVC”) filters first came on to the medical market in the 1960’s.
13 Over the years, medical device manufacturers have introduced several different designs of IVC filters.

14 14. An IVC filter is a device that is designed to filter or “catch” blood clots (called
15 “thrombi”) that travel from the lower portions of the body to the heart and lungs. IVC filters may be
16 designed to be implanted, either permanently or temporarily, in the human body, more specifically,
17 within the inferior vena cava.

18 15. The inferior vena cava is a vein that returns blood to the heart from the lower portions of
19 the body. In certain people, for various reasons, thrombi travel from the vessels in the legs and pelvis,
20 through the vena cava and into the lungs. Often times, these thrombi develop in the deep leg veins.
21 These thrombi are called “deep vein thrombosis” or “DVT”. Once thrombi reach the lungs, they are
22 considered “pulmonary emboli” or “PE”. Pulmonary emboli present risks to human health. They can,
23 and often do, result in death.

24 16. Certain people are at increased risk for the development of DVT or PE. For instance,
25 someone who undergoes knee or hip joint replacement surgery is at risk for developing DVT/PE. Obese
26 patients are also at increased risk for DVT/PE. So too are people who have vascular diseases or whom
27 have experienced previous strokes. A number of other conditions predispose people to develop
28 DVT/PE, including “coagulopathies” and clotting disorders.

1 17. Those people at risk for DVT/PE can undergo medical treatment to manage the risk. For
2 example, a doctor may prescribe medications like Heparin, Warfarin, or Lovenox to regulate the
3 clotting factor of the blood. In some people who are at high risk for DVT/PE, or who cannot manage
4 their conditions with medications, physicians may recommend surgically implanting an IVC filter to
5 prevent thromboembolic events.

6 18. As stated above, IVC filters have been on the market for decades. The first IVC filters
7 marketed were permanent filters. These devices were designed to be left in a patient's IVC permanently
8 and have long-term follow-up data (of up to 20 years and longer) supporting their use and efficacy.
9 Beginning in 2003, manufacturers also began marketing what are known as optional or retrievable
10 filters. These filters are designed so that they can be surgically removed from a patient after the risk of
11 PE has subsided. These IVC filter designs, however, were not intended to remain within the human
12 body for indeterminate periods of time. In other words, the initial designs of retrievable IVC filters
13 were intended to remain implanted for a finite period of time. Although the Recovery® Filter System
14 and the subsequent G2® Filter manufactured by Bard and BPV are examples of retrievable filters, these
15 filters were marketed as permanent filters with the option of retrieval.

16 **B. THE RECOVERY FILTER®**

17 **i. FDA Clearance and Intended Use**

18 19. In 2002, Bard and BPV submitted a notification of intent to the FDA to market the
19 “Recovery® Filter System” (hereafter “Recovery®” or “Recovery® Filter”) for the prevention of
20 recurrent pulmonary embolism by placement in the inferior vena cava.¹ On November 27, 2002, the
21 FDA cleared the Recovery® Filter for marketing and use in the prevention of recurrent pulmonary
22 embolism via *permanent* placement in the vena cava in the following situations: (a) pulmonary
23

24 ¹ Bard and BPV submitted the notification under Section 510(k) of the United States Food, Drug and
25 Cosmetic Act (“Act”) of 1976 (21 U.S.C. 321 *et seq.*). The 510(k) review process requires any entity
26 engaged in the design, manufacture, distribution or marketing of a device intended for human use to
27 notify the FDA 90 days before it intends to market the device and to establish that the device is
28 substantially equivalent to a legally marketed predicate device. (21 C.F.R. §§ 807.81, 807.92(a)(3)).
Substantial equivalence means that the new device has the same intended use and technological
characteristics as the predicate device. This approval process allows a manufacturer to bypass the
rigorous safety scrutiny required by the pre-market approval process.

1 thromboembolism when anticoagulants are contraindicated; (b) failure of anticoagulant therapy for
2 thromboembolic disease; (c) emergency treatment following massive pulmonary embolism where
3 anticipated benefits of conventional therapy are reduced; and (d) chronic, recurrent pulmonary
4 embolism where anticoagulant therapy has failed or is contraindicated.

5 20. In April 2003, Bard and BPV submitted a Section 510(k) premarket notification of intent
6 to market the Recovery® Filter for the additional intended use of *optional retrieval*. The FDA cleared
7 this additional intended use on July 25, 2003.

8 21. Bard and BPV began actually marketing the device in April 2003, but did not begin full
9 market release until 2004. Bard and BPV were aware that the Recovery® filter was also used
10 extensively off-label, including for purely prophylactic reasons for trauma patients or patients with
11 upcoming surgeries such as bariatric procedures.

12 **ii. What Is It and How Is It Used**

13 22. The Recovery® Filter consists of two (2) levels of six (6) radially distributed NITINOL
14 struts that are designed to anchor the filter into the inferior vena cava and to catch any embolizing
15 clots. There are six short struts, which are commonly referred to as the arms, and six long struts, which
16 are commonly referred to as the legs. Each strut is held together by a single connection to a cap located
17 at the top of the device. According to the Patent filed for this device, the short struts are primarily for
18 “centering” or “positioning” with the vena cava, and the long struts with attached hooks are designed to
19 primarily to prevent the device from migrating in response to “normal respiratory movement” or
20 “pulmonary embolism.”

21 23. As noted above, the Recovery® Filter is constructed with NITINOL, which is an
22 acronym that stands for Nickel Titanium Naval Ordnance Laboratory. NITINOL possesses “shape
23 memory.” That is, NITINOL will change shape according to changes in temperature, and then, retake
24 its prior shape after returning to its initial temperature. When placed in saline, therefore, the NITINOL
25 struts become soft and can be straightened to allow delivery through a small diameter catheter. The
26 metal struts then reassume their original shape when warmed to body temperature in the vena cava.

27 24. The Recovery® filter is inserted by a catheter that is guided by a physician through a
28 blood vessel into the inferior vena cava. The Recovery® Filter is designed to be retrieved in a similar

fashion. The implanting physician normally reviews an imaging study prior to placement to determine size of IVC, renal vein location, and to identify any venous anomalies or clots in the vena cava. Following placement, the physician will normally use an imaging study to confirm successful placement.

iii. Inherent Risks of the Recovery® Filter

25. The Recovery® Filter is prone to an unreasonably high risk of failure and patient injury following placement in the human body. Multiple studies have reported Bard's Recovery® Filter to have a fracture and migration rate ranging from 21% to 31.7%.² When such failures occur, shards of the device or the entire device can travel to the heart, where it can cause cardiac tamponade, perforation of the atrial wall, myocardial infarction and death. These fractured shards may also become too embedded in tissue or migrate to locations, such as the lungs, such that they are too dangerous to remove. These patients are exposed to a lifetime of future risk.

26. The Recovery® Filter similarly poses a high risk of tilting and perforating the vena cava walls. When such failures occur, the device can perforate the duodenum, small bowel, ureter, which may lead to retroperitoneal hematomas, small-bowel obstructions, extended periods of severe pain, and/or death. Further, given the risks of injury in attempting to remove devices that have perforated the vena cava, the device may be irremovable. These patients are faced with a lifetime of future risk.

27. The Recovery Filter failures described above occur at a substantially higher rate than with other IVC filters.

28. The adverse event reports (AERs) associated with IVC filter devices demonstrates that Bard's IVC Filters are far more prone to device failure than are other similar devices. A review of the FDA MAUDE database from the years 2004-2008 reveals data to establish that Bard's IVC filters are responsible for the following percentages of all AERs:

- a. 50% of all adverse events
- b. 64% of all occurrences of migration of the device

² See e.g., Hull JE, Robertson SW. Bard Recovery Filter: evaluation and management of vena cava limb perforation, fracture, and migration. *J Vasc Interv Radiol.* 2009;20(1):52-60; Nicholson W, *et al.* Prevalence of Fracture and Fragment Embolization of the Bard Recovery and Bard G2 Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade. *Arch. Int. Med.* 2010 Nov.; 170:1827-31.

- c. 69% of all occurrences of vena cava wall perforation
- d. 70% of all occurrences of filter fracture.

29. These failures are attributable, in part, to the fact that the Recovery® Filter was designed so as to be unable to withstand the normal anatomical and physiological loading cycles exerted *in vivo*.

30. In addition to design defects, the Recovery® Filter suffers from manufacturing defects. These manufacturing defects include, but are not limited to, the existence of “draw markings” and circumferential grinding markings on the exterior of the surface of the device. The presence of these draw markings and/or circumferential grinding markings further compromises the structural integrity of the device while *in vivo*. In particular, the Recovery Filter is prone to fail at or near the location of draw markings/circumferential grinding markings on the struts of the device. Put simply, the Recovery Filter is not of sufficient strength to withstand normal placement within the human body. The presence of the aforementioned exterior manufacturing defects makes the device more susceptible to failure.

iv. What Bard and BPV Knew or Should Have Known

31. Bard and BPV knew that no clinical testing, such as animal studies, was conducted to determine whether the Recovery® Filter would perform safely once implanted in the human body and subjected normal *in vivo* stresses.

32. Soon after the Recovery® Filter’s introduction to the market in 2003, Bard and BPV began receiving large numbers of adverse event reports (“AERs”) from health care providers reporting that the Recovery® Filter was fracturing post-implantation and that fractured pieces and/or the entire device were migrating throughout the human body, including to the heart and lungs. Bard and BPV also received large numbers of AERs reporting that the Recovery® Filter was found to have excessively tilted and/or perforated the inferior vena cava post-implantation. These failures were often associated with reports of severe patient injuries such as:

- a. death;
- b. hemorrhage;
- c. cardiac/pericardial tamponade (pressure caused by a collection of blood in the area around the heart);
- d. cardiac arrhythmia and other symptoms similar to myocardial infarction;
- e. severe and persistent pain;

f. and perforations of tissue, vessels and organs.

33. Within the first year of full market release of the Recovery® Filter, Bard and BPV received at least 32 AERs reporting that the Recovery® Filter had fractured *in vivo* and at least 22 AERs reporting that the entire device had migrated *in vivo*. Of the 22 reported migration failures, at least nine (9) were reported to have been associated with patient death.

34. From 2003 through September 2005, Bard and BPV received ever growing numbers of AERs reporting the above described failures and patient injuries. Defendants knew or should have known that the failure rates associated with the Recovery® Filter were substantially higher than other similar products on the market and that there were safer alternative devices, including the Simon Nitinol Filter manufactured and distributed by Bard and BPV.

v. Market Withdrawal, but no Recall

35. In late 2004 or early 2005 Bard and BPV, without notifying consumers of the design and manufacturing flaws inherent in the Recovery® Filter, began redesigning the Recovery® Filter in an attempt to correct those flaws. The redesigned filter is known as the G2® Filter, which stands for second generation Recovery® Filter. Once Bard and BPV had obtained FDA approval to market the redesigned product in or around August 2005, Bard and BPV quietly stopped marketing the Recovery® Filter. Bard and BPV failed, however, to make any effort to notify consumers of the risk inherent in the use of the Recovery® Filter.

C. THE G2® FILTER SYSTEM

36. On August 10, 2005, Bard and BPV submitted a Section 510(k) premarket notification of intent to market the G2® Filter for the prevention of recurrent pulmonary embolism via placement in the inferior vena cava. Bard and BPV cited the Recovery® Filter as the substantially equivalent predicate device. Bard and BPV stated that the differences between the Recovery® Filter and the G2® Filter were primarily dimensional and no material changes or additional components were added. On

1 August 29, 2005, the FDA cleared the Recovery® Filter for the same intended uses as the Recovery®
2 Filter, except that it was not cleared for retrievable use.³

3 37. Bard and BPV marketed the G2® Filter as having “enhanced fracture resistance,”
4 “improved centering,” and “increased migration resistance.” However, Bard and BPV again failed to
5 conduct adequate clinical testing, such as animal studies, to ensure that the device would perform safely
6 and effectively once implanted in the human body and subjected *in vivo* stresses. Not surprisingly, the
7 G2® Filter’s design causes it to be of insufficient integrity and strength to withstand normal *in vivo*
8 body stresses within the human body so as to resist fracturing, migrating, tilting, and/or perforating the
9 inferior vena cava.

10 38. Also, like its predecessor, in addition to design defects, the G2® Filter suffers from
11 manufacturing defects. These manufacturing defects include, but are not limited to, the existence of
12 “draw markings” and circumferential grinding markings on the exterior of the surface of the device.
13 The presence of these draw markings and/or circumferential grinding markings further compromises
14 the structural integrity of the G2® Filter while *in vivo*. In particular, the G2® Filter is prone to fail at
15 or near the location of draw markings/circumferential grinding markings on the struts of the device.
16 Put simply, the G2® Filter is not of sufficient strength to withstand normal placement within the human
17 body. The presence of the aforementioned exterior manufacturing defects makes the device more
18 susceptible to fatigue failure.

19 39. Thus, the G2® Filter shares the same defects and health risks as its predicate device.

20 40. As with the Recovery® Filter, Bard and BPV immediately began receiving large
21 numbers of AERs reporting that the G2® Filter was, *inter alia*, fracturing, migrating, excessively
22 tilting, and perforating the vena cava once implanted. These failures were again often associated with
23 reports of severe patient injuries such as:

- 24 a. death;
- 25 b. hemorrhage;
- 26 c. cardiac/pericardial tamponade (pressure caused by a collection of blood in the
27 area around the heart);

28 ³ The FDA did not clear the G2® Filter to be used as a retrievable filter until January 15, 2008.

- d. cardiac arrhythmia and other symptoms similar to myocardial infarction;
- e. severe and persistent pain;
- f. and perforations of tissue, vessels and organs.

41. Defendants represent the fracture rate of the G2® Filter to be 1.2%. Based upon a review of the data available in the public domain (including the FDA MAUDE database statistics and the published medical literature), this representation does not accurately reflect the true incidence of device fracture for the G2® Filter.

42. A review of the MAUDE database from the years 2004-2008 reveals data to establish that the Bard and BPV's vena cava filters (including the G2® Filter) are responsible for the majority of all reported adverse events related to inferior vena cava filters and that there were safer alternative devices, including the Simon Nitinol Filter manufactured and distributed by Bard and BPV.

D. BARD AND BPV'S KNOWLEDGE OF THE RISK OF FAILURE AND RESULTING DANGERS

43. Upon information and belief, Plaintiffs allege that as early as 2003, Bard and BPV were aware and had knowledge of the fact that the Recovery® Filter was defective and unreasonably dangerous and was causing injury and death to patients who had received it. Similarly, Bard and BPV were aware as early as 2005 that the G2® Filter System was defective and unreasonably dangerous and was causing injury and death to patients who had received it.

44. Data establishes that the failure rates of the Recovery® Filter and G2® Filter are/were exceedingly higher than the rate that Bard and BPV have in the past, and currently continue to publish to the medical community, members of the public. Further, Bard and BPV were aware or should have been aware that the Recovery® Filter and G2® Filter have substantially higher failure rates than do other similar products on the market, yet Defendants have failed to warn consumers of this fact.

45. Upon information and belief, from the time the G2® Filter System became available on the market, the Defendants Bard and BPV embarked on an aggressive campaign of "off label marketing" concerning the G2® Filter System. This included representations made to physicians, healthcare professionals, and other members of the medical community that the G2® Filter System was

1 safe and effective for retrievable use prior to the FDA approving the G2® Filter System for retrievable
2 use.

3 46. The conduct of Bard and BPV as alleged in this Complaint constitutes willful, wanton,
4 gross, and outrageous corporate conduct that demonstrates a conscious disregard for the safety of
5 Plaintiff. Bard and BPV had actual knowledge of the dangers presented by the Recovery Filter® and
6 G2® Filter, yet consciously failed to act reasonably to:

- 7 a. Inform or warn Plaintiff, her physicians, or the public at large of these dangers;
8 b. Establish and maintain an adequate quality and post-market surveillance system;
9 and
10 c. Recall the Recovery® Filter and G2® Filter from the market.

11 47. Despite having knowledge as early as 2003 of the unreasonably dangerous and defective
12 nature of the Recovery® Filter, Bard and BPV consciously disregarded the known risks and continued
13 to actively market and offer for sale the Recovery® and G2® Filter Systems.

14 48. Plaintiffs further allege that the Defendants acted in willful, wanton, gross and total
15 disregard for the health and safety of the users or consumers of their Recovery® Filter and G2® Filter
16 Systems, acted to serve their own interests, and having reason to know and consciously disregarding
17 the substantial risk that their product might kill or significantly harm patients, or significantly injure the
18 rights of others, consciously pursued a course of conduct knowing that such conduct created a
19 substantial risk of significant harm to other persons.

20 **SPECIFIC FACTUAL ALLEGATIONS AS TO LINDA SCHWESKA**

21 49. On November 10, 2006, Bard G2® Filter was implanted in plaintiff.

22 50. This G2® Filter device was designed, manufactured, prepared, compounded, assembled,
23 processed, marketed, distributed, and sold by Defendants Bard and BPV.

24 51. There were three failed explant attempts to remove the G2® filter. The first and second
25 failed attempt to remove the G2® filter on January 2, 2007. The third failed attempt to remove the G2®
26 filter occurred on March 7, 2007. The G2 Filter System® subsequently failed and a fourth attempt to
27 remove the filter became necessary through open procedure. Specifically, the inferior vena cava filter
28 had migrated and the tip of the filter was so embedded that retrieval was very difficult for the Plaintiff's

1 physicians. Plaintiffs have incurred significant medical expenses and have endured extreme pain and
2 suffering, loss of enjoyment of life, disability, and other losses.

3 **FRAUDULENT CONCEALMENT**

4 52. Any applicable statutes of limitation have been tolled by the knowing and active
5 concealment and denial of material facts known by Defendants when they had a duty to disclose those
6 facts. They have kept Plaintiff ignorant of vital information essential to the pursuit of her claim,
7 without any fault or lack of diligence on Plaintiffs' part, for the purpose of obtaining delay on
8 Plaintiffs' part in filing on their causes of action. Defendants' fraudulent concealment did result in such
9 delay.

10 53. Defendants are estopped from relying on the statute of limitations defense because
11 Defendants failed to timely disclose, among other things, facts evidencing the defective and
12 unreasonably dangerous nature of the Recovery® and G2® Filter Systems.

13 54. Linda Schweska and her health care providers could not reasonably have discovered the
14 claims made herein until at the earliest the date of December 23, 2010.

15 55. The Defendants are and were under a continuing duty to disclose the true character,
16 quality and nature of the device that was implanted in Plaintiff, but instead they concealed them.
17 Defendants' conduct, as described in this complaint, amounts to conduct purposely committed, which
18 Defendants must have realized was dangerous, heedless and reckless, without regard to the
19 consequences or the rights and safety of Plaintiff.

20 **CORPORATE/VICARIOUS LIABILITY**

21 56. At all times herein mentioned, each of the Defendants was the agent, servant, partner,
22 aider and abettor, co-conspirator and/or joint venturer of each of the other Defendants herein and was at
23 all times operating and acting within the purpose and scope of said agency, service, employment,
24 partnership, conspiracy and/or joint venture and rendered substantial assistance and encouragement to
25 the other Defendants, knowing that their collective conduct constituted a breach of duty owed to the
26 Plaintiff.

27 57. There exists and, at all times herein mentioned, there existed a unity of interest in
28 ownership between certain Defendants and other certain Defendants such that any individuality and

1 separateness between the certain Defendants has ceased and these Defendants are the alter ego of the
2 other certain Defendants and exerted control over those Defendants. Adherence to the fiction of the
3 separate existence of these certain Defendants as entities distinct from other certain Defendants will
4 permit an abuse of the corporate privilege and would sanction a fraud and/or would promote injustice.

5 58. At all times herein mentioned, Defendants, and each of them, were engaged in the
6 business of, or were successors in interest to, entities engaged in the business of researching, designing,
7 formulating, compounding, testing, manufacturing, producing, processing, assembling, inspecting,
8 distributing, marketing, labeling, promoting, packaging, prescribing and/or advertising for sale, and
9 selling products for use by the Plaintiff. As such, each Defendant is individually, as well as jointly and
10 severally, liable to the Plaintiffs for their damages.

11 59. At all times herein mentioned, the officers and/or directors of the Defendants named
12 herein participated in, authorized and/or directed the production and promotion of the aforementioned
13 products when they knew, or with the exercise of reasonable care and diligence should have known, of
14 the hazards and dangerous propensities of said products, and thereby actively participated in the
15 tortious conduct that resulted in the injuries suffered by the Plaintiffs.

16 **FIRST CAUSE OF ACTION**
17 **NEGLIGENCE**

18 60. Plaintiffs re-allege and incorporates by reference each and every allegation contained in
19 the foregoing paragraphs as though fully set forth herein.

20 61. At all times relevant to this cause of action, the Defendants Bard, BPV, and DOES 1 -
21 100 were in the business of designing, developing, setting specifications, manufacturing, marketing,
22 selling, and distributing the Recovery® and G2® Filters.

23 62. Defendants designed, manufactured, marketed, inspected, labeled, promoted, distributed
24 and sold the G2® Filter implanted in Linda Schweska.

25 63. Defendants had a duty to exercise reasonable and prudent care in the development,
26 testing, design, manufacture, inspection, marketing, labeling, promotion, distribution and sale of the
27 Recovery® Filter and G2® Filter System so as to avoid exposing others to foreseeable and unreasonable
28 risks of harm.

64. Defendants knew or reasonably should have known that the Recovery® Filter and G2® Filter System was dangerous or was likely to be dangerous when used in its intended or reasonably foreseeable manner.

65. At the time of manufacture and sale of the Recovery® Filter and G2® Filter System, Defendants knew or should have known that its IVC Filter:

- a. Was designed and manufactured in such a manner so as to present an unreasonable risk of fracture of portions of the device;
- b. Was designed and manufactured so as to present a unreasonable risk of migration of the device and/or portions of the device; and/or
- c. Was designed and manufactured so as to present a unreasonable risk of the device tilting and/or perforating the vena cava wall;
- d. Was designed and manufactured to have unreasonable and insufficient strength or structural integrity to withstand normal placement within the human body.

66. At the time of manufacture and sale of the G2® Filter (2005 to present), Defendants knew or should have known that using the G2® Filter in its intended use or in a reasonably foreseeable manner created a significant risk of a patient suffering severe health side effects, including, but not limited to: hemorrhage; cardiac/pericardial tamponade; cardiac arrhythmia and other symptoms similar to myocardial infarction; perforations of tissue, vessels and organs; and other severe personal injuries and diseases, which are permanent in nature, including, but not limited to, death, physical pain and mental anguish, scarring and disfigurement, diminished enjoyment of life, continued medical care and treatment due to chronic injuries/illness proximately caused by the device; and the continued risk of requiring additional medical and surgical procedures including general anesthesia, with attendant risk of life threatening complications.

67. Defendants knew or reasonably should have known that consumers of the Recovery® Filter and G2® Filter System would not realize the danger associated with using the device in its intended use and/or in a reasonably foreseeable manner.

68. Defendants breached their to duty to exercise reasonable and prudent care in the development, testing, design, manufacture, inspection, marketing, labeling, promotion, distribution and

1 sale of the Recovery® Filter and G2® Filter System in, among other ways, the following acts and
2 omissions:

- 3 a. Designing and distributing a product in which they knew or should have known that the
4 likelihood and severity of potential harm from the product exceeded the burden of taking
5 safety measures to reduce or avoid harm;
- 6 b. Designing and distributing a product in which they knew or should have known that the
7 likelihood and severity of potential harm from the product exceeded the likelihood of
8 potential harm from other device available for the same purpose;
- 9 c. Failing to use reasonable care in manufacturing the product and producing a product that
10 differed from their design or specifications or from other typical units from the same
11 production line;
- 12 d. Failing to use reasonable care to warn or instruct, including pre and post sale, Plaintiff,
13 Plaintiff's physicians, or the general health care community about the Recovery® Filter
14 and G2® Filter System's substantially dangerous condition or about facts making the
15 product likely to be dangerous;
- 16 e. Failing to perform reasonable pre and post-market testing of the Recovery® Filter and
17 G2® Filter System to determine whether or not the product was safe for its intended use;
- 18 f. Failing to provide adequate instructions, guidelines, and safety precautions, including
19 pre and post sale, to those persons to whom it was reasonably foreseeable would
20 prescribe, use, and implant the Recovery® Filter and G2® Filter System;
- 21 g. Advertising, marketing and recommending the use of the Recovery® Filter and G2®
22 Filter System, while concealing and failing to disclose or warn of the dangers known by
23 Defendants to be connected with and inherent in the use of its IVC Filters;
- 24 h. Representing that the Recovery® Filter and G2® Filter System was safe for its intended
25 use when in fact, Defendants knew and should have known the product was not safe for
26 its intended purpose;
- 27 i. Continuing manufacture and sale of the Recovery® Filter and G2® Filter System with
28 the knowledge that said product was dangerous and not reasonably safe, and failing to
comply with FDA good manufacturing regulations;
- j. Failing to use reasonable and prudent care in the design, research, manufacture, and
development of the Recovery® Filter and G2® Filter System so as to avoid the risk of
serious harm associated with the use of its IVC Filters;
- k. Advertising, marketing, promoting and selling Recovery® Filter and G2® Filter System
for uses other than as approved and indicated in the product's label;

1 l. Failing to establish an adequate quality assurance program used in the manufacturing of
2 the Recovery® Filter and G2® Filter System.

3 m. Failing to establish and maintain an adequate post-market surveillance program.

4 69. A reasonable manufacturer, distributor, or seller under the same or similar circumstances
5 would not have engaged in the before-mentioned acts and omissions.

6 70. As a direct and proximate result of the foregoing negligent acts and omissions by
7 Defendants, Plaintiffs suffered and will continue to suffer serious physical injuries, economic loss, loss
8 of enjoyment of life, disability, and other losses, in an amount to be determined at trial.

9 **SECOND CAUSE OF ACTION**
10 **STRICT PRODUCTS LIABILITY - FAILURE TO WARN**

11 71. Plaintiffs re-allege and incorporate by reference each and every allegation contained in
12 the foregoing paragraphs as though fully set forth herein.

13 72. Defendants designed, set specifications, manufactured, prepared, compounded,
14 assembled, processed, marketed, labeled, distributed, and sold the G2® Filter, including the one
15 implanted in Linda Schweska, into the stream of commerce and in the course of same, directly
16 advertised and marketed the device to consumers or persons responsible for consumers.

17 73. At the time Defendants designed, manufactured, prepared, compounded, assembled,
18 processed, marketed, labeled, distributed, and sold the device into the stream of commerce, Defendants
19 knew or should have known the device presented an unreasonable danger to users of the product when
20 put to its intended and reasonably anticipated use. Specifically, Defendants knew or should have
21 known at the time they manufactured, labeled, distributed and sold the G2® Filter, which was
22 implanted in Plaintiff, that the G2® Filter, *inter alia*, posed a significant and higher risk than other
23 similar devices of device failure (fracture, migration, tilting, and perforation of the vena cava wall) and
24 resulting serious injuries. Upon information and belief, Defendants also knew or should have known
25 that certain conditions or post-implant procedures, such as morbid obesity or open abdominal
26 procedures, could affect the safety and integrity of the device.

27 74. Therefore, Defendants had a duty to warn of the risk of harm associated with the use of
28 the device and to provide adequate instructions on the safe and proper use of the device. Defendants

1 further had a duty to warn of dangers and proper safety instructions that it became aware of even after
2 the device was distributed and implanted in Plaintiff.

3 75. Despite this duty, Defendants failed to adequately warn of material facts regarding the
4 safety and efficacy of the G2® Filter, and further failed to adequately provide instructions on the safe
5 and proper use of the device.

6 76. No health care provider, including Plaintiffs, or patient would have used the device in
7 the manner directed, had those facts been made known to the prescribing healthcare providers and/or
8 ultimate users of the device.

9 77. The health risks associated with the device as described herein are of such a nature that
10 ordinary consumers would not have readily recognized the potential harm.

11 78. Plaintiff and her health care providers used the device in a normal, customary, intended,
12 and foreseeable manner, namely as a surgically implanted device used to prevent pulmonary
13 embolisms.

14 79. Therefore, the G2® Filter implanted in Plaintiff was defective and unreasonably
15 dangerous at the time of release into the stream of commerce due to inadequate warnings, labeling
16 and/or instructions accompanying the product.

17 80. The G2® Filter implanted in Plaintiff was in the same condition as when it was
18 manufactured, inspected, marketed, labeled, promoted, distributed and sold by Defendants.

19 81. As a direct and proximate result of Defendants' lack of sufficient warning and/or
20 instructions, Plaintiff Linda Schweska has suffered and will continue to suffer serious physical injuries,
21 economic loss, loss of enjoyment of life, disability, and other losses, in an amount to be determined at
22 trial.

23 **THIRD CAUSE OF ACTION**
24 **STRICT PRODUCTS LIABILITY – DESIGN DEFECTS**

25 82. Plaintiffs re-allege and incorporate by reference each and every allegation contained in
26 the foregoing paragraphs as though fully set forth herein.

27 83. At all times relevant to this action, Defendants developed, tested, designed,
28 manufactured, inspected, labeled, promoted, distributed and sold into the stream of commerce the G2®
Filter, including the one implanted in Plaintiff.

1 84. The G2® Filter was expected to, and did, reach its intended consumers without
2 substantial change in the condition in which it was in when it left Defendants' possession. In the
3 alternative, any changes that were made to G2® Filter implanted in Plaintiff were reasonably
4 foreseeable to Defendants.

5 85. The G2® Filter implanted in Plaintiff was defective in design because it failed to
6 perform as safely as persons who ordinarily use the product would have expected at the time of use.

7 86. The G2® Filter implanted in Plaintiff was defective in design, in that its risks of harm
8 exceeded its claimed benefits.

9 87. Plaintiff and her health care providers used the G2® Filter in a manner that was
10 reasonably foreseeable to Defendants.

11 88. Neither Plaintiff, nor her health care providers could have by the exercise of reasonable
12 care discovered the devices defective condition or perceived its unreasonable dangers prior to her
13 implantation with the device.

14 89. As a direct and proximate result of the G2® Filter's defective design, Plaintiffs have
15 suffered and will continue to suffer serious physical injuries, economic loss, loss of enjoyment of life,
16 disability, and other losses, in an amount to be determined at trial.

17 **FOURTH CAUSE OF ACTION**
18 **STRICT PRODUCTS LIABILITY – MANUFACTURING DEFECT**

19 90. Plaintiffs re-allege and incorporate by reference each and every allegation contained in
20 the foregoing paragraphs as though fully set forth herein.

21 91. Defendants designed, set specifications, manufactured, prepared, compounded,
22 assembled, processed, marketed, labeled, distributed, and sold the G2® Filter that was implanted into
23 Plaintiff.

24 92. The G2® Filter implanted in Plaintiffs contained a condition, which Defendants did not
25 intend, at the time it left Defendants' control and possession.

26 93. Plaintiff and her health care providers used the device in a manner that was reasonably
27 foreseeable to Defendants.
28

1 94. As a result of this condition, the product injured Plaintiff and failed to perform as safely
2 as the ordinary consumer would expect when used in a reasonably foreseeable manner.

3 95. As a direct and proximate result of the G2® Filter's manufacturing defect, Plaintiff
4 Linda Schweska has suffered and will continue to suffer serious physical injuries, economic loss, loss
5 of enjoyment of life, disability, and other losses, in an amount to be determined at trial.

6
7 **FIFTH CAUSE OF ACTION**
8 **BREACH OF IMPLIED WARRANTY OF MERCHANTABILITY**

9 96. Plaintiffs re-allege and incorporate by reference each and every allegation contained in
10 the foregoing paragraphs as though fully set forth herein.

11 97. At all times relevant to this action, Defendants designed, researched, developed,
12 manufactured, tested, labeled, inspected, advertised, promoted, marketed, sold, and distributed into the
13 stream of commerce the G2® Filter for use as a surgically implanted device used to prevent pulmonary
14 embolisms and for uses other than as approved and indicated in the product's instructions, warnings,
15 and labels.

16 98. At the time and place of the sale, distribution, and supply of the Defendants' G2® Filter
17 System to Plaintiff by way of her health care providers and medical facilities, Defendants expressly
18 represented and warranted, by labeling materials submitted with the product, that the G2® Filter
19 System was safe and effective for its intended and reasonably foreseeable use.

20 99. Defendants knew of the intended and reasonably foreseeable use of the G2® Filter, at
21 the time they marketed, sold, and distributed the product for use by Plaintiff, and impliedly warranted
22 the product to be of merchantable quality, and safe and fit for its intended use.

23 100. Defendants impliedly represented and warranted to the healthcare community, Plaintiff
24 and her health care providers, that the G2® Filter was safe and of merchantable quality and fit for the
25 ordinary purpose for which the product was intended and marketed to be used.

26 101. The representations and implied warranties made by Defendants were false, misleading,
27 and inaccurate because the G2® Filter was defective, unsafe, unreasonably dangerous, and not of
28 merchantable quality, when used in its intended and/or reasonably foreseeable manner. Specifically, at

the time of Plaintiff purchase of the G2® Filter from the Defendants, through her attending physicians and medical facilities, it was not in a merchantable condition in that:

- a. It was designed in such a manner so as to be prone to a statistically high incidence of failure, including fracture, migration, excessive tilting, and perforation of the inferior vena cava;
- b. It was designed in such a manner so as to result in a statistically significant incidence of injury to the organs and anatomy; and
- c. It was manufactured in such a manner so that the exterior surface of the G2® Filter System was inadequately, improperly and inappropriately prepared and/or finished causing the device to weaken and fail.

102. Plaintiff and her health care providers reasonably relied on the superior skill and judgment of Defendants as the designers, researchers and manufacturers of the product, as to whether G2® Filter was of merchantable quality and safe and fit for its intended use, and also relied on the implied warranty of merchantability and fitness for the particular use and purpose for which the G2® Filter was manufactured and sold.

103. Defendants placed the G2® Filter into the stream of commerce in a defective, unsafe, and unreasonably dangerous condition, and the product was expected to and did reach Plaintiff without substantial change in the condition in which the G2® Filter was manufactured and sold.

104. Defendants breached their implied warranty because their G2® Filter was not fit for its intended use and purpose.

105. As a proximate result of Defendants breaching their implied warranties, Plaintiff Linda Schweska has suffered and will continue to suffer serious physical injuries, economic loss, loss of enjoyment of life, disability, and other losses, in an amount to be determined at trial.

SIXTH CAUSE OF ACTION **NEGLIGENT MISREPRESENTATION/ CONSUMER FRAUD**

106. Plaintiffs re-allege and incorporate by reference each and every allegation contained in the foregoing paragraphs as though fully set forth herein.

107. At all times relevant to this cause, and as detailed *supra*, Defendants negligently provided Plaintiff, her health care providers, and the general medical community, with false or incorrect

information, or omitted or failed to disclose material information concerning the G2® Filter, including, but not limited to, misrepresentations relating to the following subject areas:

- a. The safety of the G2® Filter;
- b. The efficacy of the G2® Filter;
- c. The rate of failure of the G2® Filter; and
- d. The approved uses of the G2® Filter.

108. The information distributed by Defendants to the public, the medical community and Plaintiff's health care providers was in the form of reports, press releases, advertising campaigns, labeling materials, print advertisements, commercial media containing material representations, which were false and misleading, and contained omissions and concealment of the truth about the dangers of the use of the G2® Filter. Defendants made the foregoing misrepresentations knowing that they were false or without reasonable basis. These materials included instructions for use and warning document that was included in the package of the G2® Filter that was implanted in Plaintiff.

109. Defendants' intent and purpose in making these misrepresentations was to deceive and defraud the public and the medical community, including Plaintiff's health care providers; to gain the confidence of the public and the medical community, including Plaintiff's health care providers; to falsely assure them of the quality of the G2® Filter and its fitness for use; and to induce the public and the medical community, including Plaintiff's healthcare providers to request, recommend, prescribe, implant, purchase, and continue to use the G2® Filter.

110. The foregoing representations and omissions by Defendants were in fact false. The G2® Filter is not safe, fit, and effective for human use in its intended and reasonably foreseeable manner. The use of the G2® Filter is hazardous to the user's health, and said device has a serious propensity to cause users to suffer serious injuries, including without limitation, the injuries Plaintiffs suffered. Further, the device has a significantly higher rate of failure and injury than do other comparable devices.

111. In reliance upon the false and negligent misrepresentations and omissions made by Defendants, Plaintiff and her health care providers were induced to, and did use the G2® Filter, thereby causing Plaintiff to sustain severe and permanent personal injuries.

112. Defendants knew and had reason to know that Plaintiff, her health care providers, and the general medical community did not have the ability to determine the true facts intentionally and/or negligently concealed and misrepresented by Defendants, and would not have prescribed and implanted same, if the true facts regarding the device had not been concealed and misrepresented by Defendants.

113. Defendants had sole access to material facts concerning the defective nature of the product and its propensity to cause serious and dangerous side effects in the form of dangerous injuries and damages to persons who are implanted with the G2® Filter.

114. At the time Defendants failed to disclose and misrepresented the foregoing facts, and at the time Plaintiff used the G2® Filter, Plaintiff and her health care providers were unaware of said Defendants' negligent misrepresentations and omissions.

115. Plaintiff, her health care providers and general medical community reasonably relied upon misrepresentations and omissions made by Defendants where the concealed and misrepresented facts were critical to understanding the true dangers inherent in the use of the G2® Filter.

116. Plaintiff and her health care provider's reliance on the foregoing misrepresentations and omissions by Defendants' was the direct and proximate cause of Plaintiff's injuries as described herein.

SEVENTH CAUSE OF ACTION
LOSS OF CONSORTIUM

117. Plaintiff, Daniel P. Schweska re-alleges each and every allegation in this Complaint and incorporates each allegation into this Count, as if set forth at length, in its entirety.

118. Daniel P. Schweska is and was at all times relevant to this action, the legal husband of Linda Schweska, and they have at all times relevant to this action, lived together as husband and wife.

119. As a proximate result of the personal injuries suffered by Linda Schweska, as described in this complaint, Daniel P. Schweska has been deprived of the benefits of their marriage including her love, affection, society, and consortium, and other wifely duties and actions. Linda Schweska provided Daniel P. Schweska with all of the benefits of a marriage between husband and wife, prior to her implantation with the defective and unreasonably dangerous G2® Filter and resulting injuries described herein.

1 120. Daniel P. Schweska has also suffered the permanent loss of his wife's daily and regular
2 contribution to the household duties and services, which each provides to the household as husband and
3 wife.

4
5 121. Daniel P. Schweska has also incurred the costs and expenses related to the medical care,
6 treatment, medications, and hospitalization to which Linda Schweska was subjected for the physical
7 injuries she suffered as a proximate result of her use of the G2® Filter. Daniel P. Schweska will
8 continue to incur the future costs and expenses related to the care, treatment, medications, and
9 hospitalization of Linda Schweska due to her injuries from the G2® Filter.

10
11 122. Daniel P. Schweska has suffered loss of consortium, as described herein, including the
12 past, present, and future loss of his wife's companionship, services, society, and the ability of Linda
13 Schweska to provide him with the benefits of marriage, including *inter alia*, loss of contribution to
14 household income and loss of household services, all of which has resulted in his pain, suffering, and
15 mental and emotional distress and worry.

16
17 **PUNITIVE DAMAGES ALLEGATIONS**

18 123. Plaintiffs re-allege each and every allegation in this Complaint and incorporates each
19 allegation into this Count, as if set forth at length, in its entirety.

20 124. Plaintiffs are entitled to an award of punitive and exemplary damages based upon
21 Defendants' intentional, willful, knowing, fraudulent, malicious acts, omissions, and conduct, and their
22 complete and total reckless disregard for the public safety and welfare.

23 125. Defendants had knowledge of, and were in possession of evidence demonstrating that,
24 the G2® Filter was defective and unreasonably dangerous and had a substantially higher failure rate
25 than did other similar devices on the market. Yet, Defendants failed to:

- 26 a. Inform or warn Plaintiff or her health care providers of the dangers;
- 27 b. To establish and maintain an adequate quality and post-market surveillance
- 28 c. Recall the G2® Filter from the market

126. Defendants acted to serve their own interests and having reasons to know and consciously disregarding the substantial risk that their product might kill or significantly harm patients, or significantly injure the rights of others, and consciously pursued a course of conduct knowing that such conduct created a substantial risk of significant harm to other persons.

127. As a direct, proximate, and legal result of Defendants' acts and omissions a described herein, and Plaintiff's implantation with Defendants' defective product, Plaintiffs have suffered and will continue to suffer serious physical injuries, economic loss, loss of enjoyment of life, disability, and other losses, in an amount to be determined at trial.

PRAYER FOR DAMAGES

WHEREFORE, Plaintiffs pray for relief on the entire complaint, as follows:

- a. Judgment to be entered against all defendants on all causes of action of this Complaint;
- b. Plaintiffs be awarded their full, fair, and complete recovery, including pain and suffering, for all claims and causes of action relevant to this action;
- c. Plaintiffs be awarded all appropriate costs, fees, expenses, and pre-judgment and post judgment interest, as authorized by law on the judgments entered in Plaintiffs' behalf; and,
- d. Such other relief the court deems just and proper.

WHEREFORE, Plaintiffs pray for relief on the entire complaint, as follows:

AS TO THE FIRST CAUSE OF ACTION FOR NEGLIGENCE AGAINST DEFENDANTS BARD, BPV AND DOES 1 THROUGH 100.

1. General damages according to proof at the time of trial;
2. Medical and other special damages, past, present, and future, according to proof at the time of trial;
3. For pre-judgment and post-judgment interest pursuant to the laws of the State of Illinois;
4. Costs of suit incurred herein;
5. Punitive damages; and

1 6. For such other and further relief as the court may deem just and proper.

2 **AS TO THE SECOND CAUSE OF ACTION FOR STRICT LIABILITY – FAILURE TO**
3 **WARN AGAINST DEFENDANTS BARD, BPV AND DOES 1 THROUGH 100.**

4 1. General damages according to proof at the time of trial;

5 2. Medical and other special damages, past, present, and future, according to proof
6 at the time of trial;

7 3. For pre-judgment and post-judgment interest pursuant to the laws of the State of
8 Illinois;

9 4. Costs of suit incurred herein;

10 5. Punitive damages; and

11 6. For such other and further relief as the court may deem just and proper.

12 **AS TO THE THIRD CAUSE OF ACTION FOR STRICT LIABILITY – DESIGN**
13 **DEFECT AGAINST DEFENDANTS BARD BPV, AND DOES 1 THROUGH 100.**

14 1. General damages according to proof at the time of trial;

15 2. Medical and other special damages, past, present, and future, according to proof
16 at the time of trial;

17 3. For pre-judgment and post-judgment interest pursuant to the laws of the State of
18 Illinois;

19 4. Costs of suit incurred herein;

20 5. Punitive damages; and

21 6. For such other and further relief as the court may deem just and proper.

22 **AS TO THE FOURTH CAUSE OF ACTION FOR STRICT LIABILITY –**
23 **MANUFACTURING DEFECT AGAINST DEFENDANTS BARD, BPV AND DOES 1**
24 **THROUGH 100.**

25 1. General damages according to proof at the time of trial;

26 2. Medical and other special damages, past, present, and future, according to proof
27 at the time of trial;

28 3. For pre-judgment and post-judgment interest pursuant to the laws of the State of

1 Illinois;

2 4. Costs of suit incurred herein;

3 5. Punitive damages; and

4 6. For such other and further relief as the court may deem just and proper.

5 **AS TO THE FIFTH CAUSE OF ACTION FOR BREACH OF IMPLIED WARRANTY**
6 **AGAINST DEFENDANTS BARD, BPV AND DOES 1 THROUGH 100.**

7 1. General damages according to proof at the time of trial;

8 2. Medical and other special damages, past, present, and future, according to proof
9 at the time of trial;

10 3. For pre-judgment and post-judgment interest pursuant to the laws of the State of
11 Illinois;

12 4. Costs of suit incurred herein; and

13 5. For such other and further relief as the court may deem just and proper.

14 **AS TO THE SIXTH CAUSE OF ACTION FOR NEGLIGENT MISREPRESENTATION/**
15 **CONSUMER FRAUD AGAINST DEFENDANTS BARD, BPV AND DOES 1 THROUGH**
16 **100.**

17 1. General damages according to proof at the time of trial;

18 2. Medical and other special damages, past, present, and future, according to proof
19 at the time of trial;

20 3. For pre-judgment and post-judgment interest pursuant to the laws of the State of
21 Illinois;

22 4. Costs of suit incurred herein; and

23 For such other and further relief as the court may deem just and proper.

24 **AS TO THE SEVENTH CAUSE OF ACTION FOR LOSS OF CONSORTIUM**
25 **AGAINST DEFENDANTS BARD, BPV AND DOES 1 THROUGH 100.**

26
27 1. General damages including loss of consortium according to proof at the time of trial;

28 2. Medical and other special damages, past, present, and future, according to proof

1 at the time of trial;

2 3. For pre-judgment and post-judgment interest pursuant to the laws of the State of
3 Illinois;

4 4. Costs of suit incurred herein; and

5 For such other and further relief as the court may deem just and proper.

6 **DEMAND FOR JURY TRIAL**

7 Plaintiff hereby demands trial by jury on all issues.

8
9 Dated: June 25, 2015.

10 By: /s/ Robert D. Rowland
11 Robert D. Rowland, Esq. #6198915
12 Goldenberg Heller Antognoli & Rowland, P.C.
13 2227 South State Route 157
14 P.O. Box 959
15 Edwardsville, IL 62025
16 Telephone: 618-656-5150
17 Facsimile: 618-656-6230
18 Email: rrowland@ghalaw.com

19 To be admitted Pro Hac Vice:

20 Teresa C. Toriseva, Esq.
21 TORISEVA LAW
22 1446 National Road
23 Wheeling, WV 26003
24 Telephone: (304) 238-0066
25 Email: ceo@torisevalaw.com

26 John A. Dalimonte, Esq.
27 KARON & DALIMONTE LLP
28 85 Devonshire Street, Suite 1000
Boston, MA 02109
Tel: 617-367-3311
Fax: 617-742-9130
Email: johndalimonte@kdlaw.net
Counsel for Plaintiff